# SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/SCYX/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635-c-4
Ticker: SCYX
Company: SCYNEXIS
Source: SCYNEXIS
Published: 2026-05-07 01:15 EST
Original Source URL: https://ir.scynexis.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-30 12:00 EST — [SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)](https://biopharmsignal.com/news/SCYX/scynexis-initiates-phase-1-study-of-scy-770-a-novel-ampk-activator-for-the-treat-9e4687ee) — Source: SCYNEXIS
- 2026-05-22 20:15 EST — [SCYNEXIS Announces One-for-Eight Reverse Stock Split](https://biopharmsignal.com/news/SCYX/scynexis-announces-one-for-eight-reverse-stock-split) — Source: SCYNEXIS
- 2026-05-11 20:23 EST — [SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SCYX/scynexis-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: SCYNEXIS
- 2026-05-07 01:15 EST — [SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SCYX/scynexis-announces-inducement-awards-under-nasdaq-listing-rule-5635-c-4) — Source: SCYNEXIS
- 2026-03-31 10:45 EST — [SCYNEXIS Announces $40.0 Million Private Placement](https://biopharmsignal.com/news/SCYX/scynexis-announces-40-0-million-private-placement) — Source: SCYNEXIS
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)